Search

everythinglearnresearchcommunity

for

Search:↓

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The user shared progress pictures after 8 months of using oral minoxidil, initially finasteride, and then switching to dutasteride 3 times a week. They experienced some shedding but noticed healthier hair and are considering increasing the dutasteride dosage.

The user is documenting their hair loss progress using 0.5mg oral dutasteride daily. They shared pictures and received encouragement.

The post discusses an 11-month hair loss treatment journey using dutasteride, minoxidil, nizoral, and 1.5mm derma rolling. The responses inquire about the frequency of derma rolling and express optimism for further progress.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Pyluritamide and RU58841 are compared for effectiveness in addition to dutasteride for hair loss treatment. Reddit users report great results with RU58841, but data suggests pyluritamide may have better affinity.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

A user shared successful hair regrowth results after 9 months using 0.5mg Dutasteride and 2.5mg Minoxidil daily, with no side effects. The user chose Dutasteride over Finasteride for its potency and perceived lower side effects.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

The user switched from finasteride to DIY dutasteride mesotherapy and topical minoxidil due to side effects. They report improved well-being and no hair loss worsening after stopping finasteride.

Dutasteride is more effective than finasteride for hair loss, with some users experiencing fewer side effects. Users share experiences with dutasteride, finasteride, minoxidil, and biotin, discussing dosage and fertility concerns.

The conversation is about a person sharing before and after pictures of their hair loss treatment, which includes Minoxidil, Finasteride, and Dutasteride. They discuss their own hair loss, particularly the recession of their temporal points.

Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

The conversation humorously discusses using anal administration of Dutasteride as a novel method for treating hair loss, suggesting it could target DHT production more effectively. It includes satirical comments about the method's potential effects and absurd outcomes.

Missing one day of finasteride is humorously discussed, with suggestions to use additional treatments like dutasteride, RU58841, minoxidil, and microneedling. Some users jokingly suggest shaving the head or traveling for hair restoration.

A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

User has hair loss, finasteride for 5 years not effective. Considers trying dutasteride, minoxidil, or pyrilutamide.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.